Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12773346 | 1.00 | PEPD (0.45) | PEPDNR1I2CYP3A4CYP2C9ABCB11 | |
| SCHEMBL1981741 | 0.95 | PEPD (0.42) | PEPDNR1I2CYP3A4CYP2C9ABCB11 | |
| SCHEMBL1981957 | 0.93 | PEPD (0.40) | PEPDNR1I2CYP3A4CYP2C9ABCB11 | |
| SCHEMBL1646971 | 0.92 | PEPD (0.39) | PEPDNR1I2CYP3A4CYP2C9ABCB11 | |
| SCHEMBL12098526 | 0.92 | PEPD (0.39) | PEPDNR1I2CYP3A4CYP2C9ABCB11 | |
| SCHEMBL1981085 | 0.92 | PEPD (0.39) | PEPDNR1I2CYP3A4CYP2C9ABCB11 | |
| SCHEMBL12773338 | 0.90 | PEPD (0.56) | PEPDNR1I2CYP3A4CYP2C9ABCB11 | |
| SCHEMBL15746350 | 0.90 | PEPD (0.45) | PEPDNR1I2CYP3A4CYP2C9ABCB11 | |
| SCHEMBL1979535 | 0.89 | CYP3A4 (0.37) | PEPDNR1I2CYP3A4CYP2C9ABCB11 | |
| SCHEMBL18822562 | 0.88 | PEPD (0.43) | PEPDNR1I2CYP3A4CYP2C9ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079744-A1 | METHOD OF PREPARATION FOR LEDIPASVIR AND DERIVATIVE THEREOF, AND INTERMEDIATE COMPOUND FOR PREPARATION OF LEDIPASVIR | SHANGHAI FOREFRONT PHARMACEUTICAL CO LTD (CN) | 2018-03-22 | — | — | US | disclosed |
| US-20180079744-A1 | METHOD OF PREPARATION FOR LEDIPASVIR AND DERIVATIVE THEREOF, AND INTERMEDIATE COMPOUND FOR PREPARATION OF LEDIPASVIR | SHANGHAI FOREFRONT PHARMACEUTICAL CO LTD (CN) | 2018-03-22 | — | — | US | disclosed |
| EP-3272747-A1 | METHOD OF PREPARATION FOR LEDIPASVIR AND DERIVATIVE THEREOF, AND INTERMEDIATE COMPOUND FOR PREPARATION OF LEDIPASVIR | Shanghai Forefront Pharmceutical Co., Ltd (CN) | 2018-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079744-A1 | METHOD OF PREPARATION FOR LEDIPASVIR AND DERIVATIVE THEREOF, AND INTERMEDIATE COMPOUND FOR PREPARATION OF LEDIPASVIR | POLI, SAMHD1, TYMP | PEPD 70/4885NR1I2 2366/4885CYP3A4 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.